Caris Life Sciences, Inc.CAIEarnings & Financial Report
Nasdaq
NextMar 31, 2026
CAI Q3 2025 Key Financial Metrics
Revenue
$216.8M
Gross Profit
N/A
Operating Profit
$32.6M
Net Profit
$24.3M
Gross Margin
N/A
Operating Margin
15.1%
Net Margin
11.2%
YoY Growth
113.4%
EPS
$0.08
Financial Flow
Caris Life Sciences, Inc. Q3 2025 Financial Summary
Caris Life Sciences, Inc. reported revenue of $216.8M for Q3 2025, with a net profit of $24.3M (11.2% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $216.8M |
|---|---|
| Net Profit | $24.3M |
| Gross Margin | N/A |
| Operating Margin | 15.1% |
| Report Period | Q3 2025 |
Income Statement
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Revenue | $100.0M | $101.6M | $181.4M | $216.8M |
| YoY Growth | N/A | N/A | 81.3% | 113.4% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|
| Assets | N/A | N/A | $955.1M | $984.6M |
| Liabilities | N/A | N/A | $502.2M | $506.2M |
| Equity | $-2.36B | $-2.44B | $452.9M | $478.4M |
Cash Flow
| Q3 2025 | |
|---|---|
| Operating CF | $62.4M |